Be part of the knowledge.™

Oncology and Hematology

1888

LikeLikedUnlike

Episodes 196-210 of 260

Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
MinuteCE®
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGFInhibitors
- Ghassan K. Abou-Alfa, MD
  Peer
- Aiwu Ruth He, MD, PhD
  Peer
1.00 program credits
Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
MinuteCE®
Pivotal Data Supporting First-Line Durvalumab/Tremelimumab in Unresectable HCC
- Ghassan K. Abou-Alfa, MD
  Peer
1.00 program credits
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
CME/CE Broadcast Replay
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
- Jennifer Caudle, DO
  Peer
- Patricia A. Mangan, RN, MSN, APRN-BC
  Peer
1.00 credits
Tailoring Your Perioperative Immunotherapy Approach for Resectable NSCLC
MinuteCE®
Tailoring Your Perioperative Immunotherapy Approach for Resectable NSCLC
- Mark Awad, MD, PhD
  Peer
- Jessica S. Donington, MD, MSCR
  Peer
0.50 program credits
Predicting Response to Neoadjuvant and Perioperative Chemoimmunotherapy
MinuteCE®
Predicting Response to Neoadjuvant and Perioperative Chemoimmunotherapy
- Mark Awad, MD, PhD
  Peer
0.50 program credits
Perioperative Immunotherapy for Resectable NSCLC: Evaluating Approved and Emerging Approaches
MinuteCE®
Perioperative Immunotherapy for Resectable NSCLC: Evaluating Approved and Emerging Approaches
- Mark Awad, MD, PhD
  Peer
0.50 program credits
MinuteCE®
A Personalized Approach to Perioperative Immunotherapy in Early-Stage Resectable NSCLC
- Mark Awad, MD, PhD
  Peer
- Jessica S. Donington, MD, MSCR
  Peer
0.50 credits 4 episodes
When Adjuvant Immunotherapy for Resectable NSCLC May Be the Better Approach
MinuteCE®
When Adjuvant Immunotherapy for Resectable NSCLC May Be the Better Approach
- Jessica S. Donington, MD, MSCR
  Peer
0.50 program credits
APPlexus Hot Topics 2024: Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL
CME/CE
APPlexus Hot Topics 2024: Clinical Updates on Non-Covalent BTK Inhibitors in CLL and MCL
- Sandra E. Kurtin, PhD, ANP-BC, FAPO
  Peer
- Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO
  Peer
1.00 credits
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
CME/CE
CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting
- Matthew Lunning, DO, FACP
  Peer
0.50 credits
WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans
MinuteCE®
WHIM Syndrome and CXCR4 Variants: New Insights into Cellular Changes That Can Impact Patient Treatment Plans
- Jacob R. Bledsoe, MD
  Peer
1.00 program credits
WHIM Syndrome: A Chronic Neutropenic Disorder
MinuteCE®
WHIM Syndrome: A Chronic Neutropenic Disorder
- Peter E. Newburger, MD
  Peer
1.00 program credits
You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)
MinuteCE®
You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)
- Peter E. Newburger, MD
  Peer
1.00 program credits
WHIM Syndrome Management: The First FDA Approval for Patients
MinuteCE®
WHIM Syndrome Management: The First FDA Approval for Patients
- Teresa K. Tarrant, MD
  Peer
1.00 program credits
Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)
MinuteCE®
Goals of Therapy for WHIM Syndrome (a Chronic Neutropenic Disorder)
- Teresa K. Tarrant, MD
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended